IncobotulinumtoxinA is safe and effective in Caucasian adults. Its effects have been less documented in Asian adults.
To describe the efficacy and tolerability of incobotulinumtoxinA for treating glabellar frown lines (GFLs) in South Korean adults.
South Korean adults aged 18 to 65 years with moderate-to-severe GFLs received a single dose of 10 to 28 U incobotulinumtoxinA during routine clinical practice. After 30 ± 14 days, investigators assessed the efficacy using the Global Aesthetic Improvement Scale and rated tolerability using a 4-point scale.
Six hundred seventy-three subjects were enrolled, of which 528 completed the study according to protocol. Glabellar frown lines improved in 98.7% (521/528) of subjects, with 30.8% of cases rated as “very much improved” and 47.4% as “much improved.” The extent of improvement was unaffected by sex, age, and weight but was greater when the time between GFL identification and treatment was <6 months (p < .001) and when concomitant aesthetic nondrug treatments were used (p < .001). For 94% of subjects, tolerability was good or very good. All reported adverse events were transient and mild or moderate in severity.
IncobotulinumtoxinA was well tolerated and effective for treating moderate-to-severe GFLs in Korean adults irrespective of age, sex, or weight.
*Oracle Dermatology and Plastic Surgery Center, Seoul, Korea;
†Sung Nak Kwan Plastic Surgery, Seoul, Korea;
‡4Clinics, Paris, France
Address correspondence and reprint requests to: Je-Young Park, MD, Oracle Dermatology and Plastic Surgery Center, 4F Miseung Bld, 23 Apgujeong-ro 30-gil, Gangnam-gu, Seoul, 06022, Korea, or e-mail: email@example.com
Supported by Merz Asia Pacific Pte Ltd.
J.-Y. Park is an advisory board member, speaker, and consultant for Merz Pharmaceuticals, Allergan, and Medytox Inc. J.M. Pitt is an employee of 4Clinics France, who was paid by Merz Pharmaceuticals to prepare this article. The remaining author has indicated no significant interest with commercial supporters.